Skip to main
SLN

Silence Therapeutics (SLN) Stock Forecast & Price Target

Silence Therapeutics (SLN) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Silence Therapeutics PLC demonstrates a strong portfolio with validated data indicating robust target engagement through increased levels of hepcidin and ferritin, reflecting positive trends in addressing iron deficiency without dose-limiting toxicities. The company appears to be on a clear trajectory for sustained value creation, bolstered by anticipated clinical, business development, and platform milestones, which are expected to drive significant upside. Furthermore, the presence of multiple near- and mid-term catalysts across various therapeutic areas enhances the potential for meaningful advancements and value appreciation.

Bears say

Silence Therapeutics PLC, while engaged in innovative siRNA drug development, showcases a lack of diversified revenue streams and limited commercialization success, which may impact its financial sustainability. The company’s reliance on its pipeline for future growth, particularly in niche therapeutic areas, raises concerns about potential market competition and regulatory hurdles. Furthermore, the ongoing need for significant capital investment in research and development without guaranteed returns could lead to heightened financial risk and uncertainty surrounding the company’s overall valuation.

Silence Therapeutics (SLN) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Silence Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Silence Therapeutics (SLN) Forecast

Analysts have given Silence Therapeutics (SLN) a Buy based on their latest research and market trends.

According to 5 analysts, Silence Therapeutics (SLN) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Silence Therapeutics (SLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.